Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 24, 2016 (10 years ago)

Amoxicillin for Oral Suspension USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Superpotent drug: Out of specification test result for assay during stability testing.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Amoxicillin for Oral Suspension USP, 400 mg/ 5 mL, 50 mL bottle, Rx only, Manufactured In Canada by: Teva Canada Limited, Toronto, Canada, NDC 0093-4161-76

Affected NDC 0093-4161-76

Compare with the code on your package — it is the most precise check available.

Drug: Amoxicillin Category: Antibiotic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Amoxicillin
NDC 00093-4161
400 mg/5mL Powder, for Suspension
Oral
Teva Pharmaceuticals USA, Inc. Rx
Recalling firm
Teva North America
NDC code
0093-4161-76
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1470-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Amoxicillin recalls

See all
Class II · Moderate risk

Amoxicillin Capsules

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 0781-2613-01 D-1025-2022
Class II · Moderate risk

AMOXICILLIN Tablets

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0166-2024

Other recalls by Teva North America

All 2016 recalls
Class III · Low risk

Children's Qnasl 40 mcg

Failed Content Uniformity Specifications: out of specification test result for spray content uniformity.

Terminated Wrong potency / content Teva North America NDC 59310-206-08 D-1453-2016
Class II · Moderate risk

Albuterol Sulfate Syrup

Presence of Foreign Substance; presence of black particles describes generically as cellulose-based bundles of brown fibrous material.

Terminated Particulate / foreign matter Teva North America NDC 0093-0661-16 D-1455-2016